Business
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible No
About this update from Zenas Biopharma, Inc.
[{"type":"image","alt":"Zenas BioPharma","displaySize":"","headline":null,"caption":"Zenas BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bjxJdSV_PbdPJT7f1Gm1fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NA--/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and shares of its common stock (the “Equity Offering”).","length":570,"tagName":"p"},{"type":"text","content":"In addition, Zenas intends to grant the underwriters of the Convertible Notes Offering a 30-day option to purchase up to an additional fifteen percent (15%) of Convertible Notes offered in the Convertible Notes Offering, solely to cover over-allotments. Zenas also intends to grant the underwriters of the Equity Offering a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the Equity Offering.","length":453,"tagName":"p"},{"type":"text","content":"Neither the closing of the proposed Convertible Notes Offering nor the closing of the proposed Equity Offering is conditioned upon the closing of the other offering, so it is possible that the Convertible Notes Offering occurs and the Equity Offering does not occur, and vice versa, or neither occurs, or either offering results in lower net proceeds than Zenas currently estimates. The proposed offerings are subject to market and other conditions, and there can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings.","length":594,"tagName":"p"},{"type":"text","content":"The Convertible Notes will be general, unsecured, senior obligations of...